FL
Follicular lymphoma（FL）, a subtype of non-Hodgkin's lymphoma, is the most common indolent lymphoma. FL has a longer disease duration because the tumor grows slowly in the body. FL usually relapses and becomes more aggressive with each relapse, it also can transform to an aggressive lymphoma subtype. FL is difficult to cure when it is in an advanced stage, so the current treatment landscape needs to be changed by innovation therapy.
The RELIANCE study (NCT04089215) is a prospective, single‑arm, multicenter, pivotal phase I/II study. In the FL cohort of the RELIANCE1 study2, 28 patients with r/r FL who had failed at least two lines of therapy were treated with relma-cel.
- Deep response: Relma‑cel achieved a best overall response rate (ORR) of 100% in Chinese FL patients treated with ≥3 lines of therapy&,1
- Durable benefit: With a median follow‑up of 11.7 months, the median DOR and median OS with relma‑cel were not reached1,2
- Tolerable safety: The incidence of grade ≥3 CRS and neurologic events with relma‑cel was low&,1
Note: The data above comes from the RELIANCE study, individual patient may have different results of treatment in the clinical practice based on multiple factors, including physical condition, disease status, T cell function and so on. It is recommended that you can consult the healthcare professionals if you have specific questions.
&Data from the 100×106 cell therapy dose group
1. Ying ZT, et al. Am J Hematol 2022; 97(12):E436-E438.
2. Gao F,et al. Hematol Oncol 2025; 43(2):e70051.